What Uquifa does

UQUIFA Group is a Barcelona-headquartered manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates serving the global pharmaceutical, animal health, and specialty chemicals industries. Founded in 1936 as a Spanish manufacturer of opiates and finished dosage forms, the company has evolved into a multi-continent API platform operating GMP-compliant manufacturing sites in Spain (Sant Celoni) and Hungary (Budapest, via the 2018-acquired Soneas Chemicals Ltd.), supplemented by R&D laboratories in India (Hyderabad) and Mexico (Cuernavaca). The company maintains a portfolio of 30+ off-patent generic APIs with 50+ active DMFs and 18+ CEPs filed across the US, EU, Japan, Korea, Canada, and Brazil, alongside a CDMO service offering covering route scouting, process development, scale-up, and regulatory filing support for Phase I-III innovative pharmaceutical customers.

UQUIFA's revenue model is organized around three pillars: (1) Off-Patent APIs sold under multi-jurisdictional regulatory filings to generic and ethical pharmaceutical companies; (2) CDMO services delivered as project-based and multi-year contracts covering the full lifecycle from laboratory to commercial-scale manufacturing; and (3) Other Chemical Specialities (organometallics, research chemicals, advanced intermediates) produced at the Hungary site for cosmeceutical, flavors & fragrances, and crop protection customers. Distribution is exclusively direct B2B enterprise sales, organized by business line with named account managers per region, supplemented by industry conference presence (CPhI Frankfurt, Nordic Life Science Days) and thought-leadership content marketing through a Knowledge Center.

The company is a subsidiary of Vivimed Labs Limited (India), which acquired UQUIFA Spain and Mexico in 2011, and received a minority growth investment from healthcare-focused private equity firm OrbiMed Advisors Asia in 2017. Production infrastructure comprises 80+ reactors with combined capacity exceeding 350,000 litres, supported by state-of-the-art R&D equipment including RC-1 reaction calorimetry, LC-MS, GC-MS, and Design of Experiments capability. The group employs 500+ people globally (700+ at GMP facilities) and was awarded EcoVadis Gold Medal (83/100) in February 2026.

Name

Uquifa

Legal name

Unión Químico Farmacéutica, S.A.U.

Website

https://uquifa.com

Company type

Private

Founded year

1936

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Uquifa is a Barcelona-based, 1936-founded manufacturer of Active Pharmaceutical Ingredients (APIs), intermediates, and CDMO services for global pharmaceutical, animal health, and specialty chemicals customers, operating GMP-compliant sites in Spain, Hungary, India, and Mexico.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredient (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411), Chemical Manufacturing (325)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Active pharmaceutical ingredients
• Generic API manufacturing
• CDMO services
• Pharmaceutical intermediates
• Specialty chemical manufacturing

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Off-Patent / Generic APIs: Sale of generic Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. UQUIFA maintains an extensive portfolio of 30+ generic APIs (e.g., Acyclovir, Allopurinol, Cimetidine, Ciprofloxacin, Esomeprazole Sodium, Famotidine, Linezolid, Omeprazole, Sitagliptin Phosphate, etc.) with CEP and Drug Master File (DMF) regulatory registrations for global markets including EU, US, Canada, Japan, Korea, and Brazil.
2. CDMO (Contract Development and Manufacturing Organization): Full-service CDMO offering covering route scouting, process development, analytical method development, scale-up from laboratory to pilot plant to commercial-scale, regulatory support (DMF/CTD/COS filing), stability studies, polymorphism studies, reference standard synthesis, and impurity profile characterisation. Services are billed as project-based or multi-year contract engagements.
3. Other Chemical Specialities: Specialty chemicals for non-pharmaceutical sectors. Products include research chemicals, organometallic compounds, and advanced intermediates (e.g., 2,6-Dichloro-N-trimethylsilyaniline, Ethylhydrocupreine Hydrochloride, Oxalacetic Acid, etc.) manufactured at the Hungary site.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Uquifa Group manufactures and supplies Active Pharmaceutical Ingredients (APIs) and chemical intermediates from cGMP-compliant facilities in Spain and Hungary, supported by R&D laboratories in India and Mexico. The company operates three business lines: an Off-Patent/Generic API portfolio of 30+ molecules (Acyclovir, Ciprofloxacin, Omeprazole, Sitagliptin, etc.) with CEP and DMF regulatory filings; a Pipeline Portfolio of APIs under development; and a full-service CDMO offering covering route scouting, process development, scale-up, and regulatory filing support for Phase I–III customers. Specialty chemicals for non-pharma use are supplied from the Hungary-based Soneas site.

Product overview

UQUIFA Group is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for pharmaceutical and animal health industries. The product portfolio consists of three main pillars: Off-Patent APIs (Generic APIs Portfolio) providing approved generic active pharmaceutical ingredients with regulatory documentation; Pipeline Portfolio featuring products under development across therapeutic areas; and CDMO Services offering custom development and manufacturing from early-stage R&D through commercial-scale production. The offering is complemented by Other Chemical Specialities from subsidiary Soneas Chemicals Ltd., and supported by extensive Chemistry Capabilities and Technical Toolbox infrastructure including over 80 reactors with 350,000+ litres capacity, pilot plants, and particle engineering equipment. The company operates across Spain, Hungary, and India with cGMP-compliant facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Off-Patent APIs (Generic APIs Portfolio) Active Pharmaceutical Ingredients for generic pharmaceuticals — a catalogue of 30+ generic APIs (including Acyclovir, Allopurinol, Cimetidine, Ciprofloxacin HCl, Clindamycin Phosphate, Esomeprazole Sodium, Famotidine, Linezolid, Omeprazole, Sitagliptin Phosphate, and others), supplied with regulatory documentation including CEPs, EDMFs, USDMFs, and pharmacopoeia compliance (EP, USP) for global markets.
• Pipeline Portfolio API products under development across multiple therapeutic areas, including Apixaban (Antithrombotic), Brivaracetam (Antiepilepsy), Cariprazine (Antipsychotic), Dorzolamide (Glaucoma), Eperisone HCl (Muscle-relaxant), Ketoprofen (Anti-inflammatory), Lasmiditan (Migraine), Phenyltoloxamine Citrate (Antihistamine), Levoketoconazole (Cushing's syndrome), Rivaroxaban (Anticoagulant), and Vonoprozan (Antiulcerant).
• CDMO Services Contract Development and Manufacturing Organization services covering novel synthetic route development, route optimization, scale-up from laboratory to pilot plant, scale-up from pilot plant to commercial production, technology transfer of commercial-scale processes, analytical method development, regulatory support (DMF, CTD, COS filings), stability studies, polymorphism studies, reference standard synthesis, and impurity profile characterization. Offered to innovative pharmaceutical companies at Phase I, II, and III across two continents (America and Europe).
• Other Chemical Specialities Specialty chemical products manufactured at the Hungary site, including research chemicals, organometallic compounds, and advanced intermediates such as 2,6-Dichloro-N-trimethylsilyaniline, 3-Chloro-5-acetyl-iminodibenzyl, 9-Bromo-1-nonanol, Alpha-hydroxy-benzylphosphonic acid sodium salt, Ethylhydrocupreine Hydrochloride, and Oxalacetic Acid. Targeted at cosmeceutical, flavors & fragrances, and crop protection applications.
• Bulk Intermediate Pellets (GMP-certified) Bulk intermediate Pellets manufactured at UQUIFA Spain's cGMP manufacturing facility under a renewed GMP certificate (non-sterile medicinal product for human use), valid until 28 July 2028.

Quantifiable outcome

• 83/100 EcoVadis Gold Medal score — a +14 point ESG performance increase year-over-year
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Soneas Chemicals Ltd. (Hungary)coreStrategic or Co-development Partner · 1 January 2018Soneas Chemicals Ltd., a Budapest-based CDMO company, was integrated into the UQUIFA Group in 2018. The bolt-on acquisition enhanced UQUIFA's CDMO capabilities, adding Phase 1 and 2 capabilities, new customer base, additional chemistry capabilities, and greater coverage of the CDMO sector across Europe. Soneas operates from three sites in Budapest.
• Medicines for EuropeminorOthersUQUIFA Group is a member of Medicines for Europe, an industry association representing generic and biosimilar pharmaceutical manufacturers in Europe.
• Cefic (European Chemical Industry Council)minorOthersUQUIFA Group is a member of Cefic, the European Chemical Industry Council.
• ACS (Associació de Químics i Enginyers de l'Administració de Barcelona)minorOthersUQUIFA Group is a member of ACS, the Association of Chemists and Engineers of Barcelona.
• AFAQUIMminorOthersUQUIFA Group is a member of AFAQUIM, a chemical industry association.
• COASHIQminorOthersUQUIFA Group is a member of COASHIQ.
• FedequimminorOthersUQUIFA Group is a member of Fedequim.
• FEIQUE (Federación Empresarial de la Industria Química Española)minorOthersUQUIFA Group is a member of FEIQUE, the Spanish Chemical Industry Business Federation.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Hovione: Hovione is a Portugal-headquartered, family-owned CDMO and API manufacturer with deep small-molecule expertise, integrated drug substance and particle engineering capabilities, and global GMP facilities - directly comparable to Uquifa's API + CDMO + particle engineering model.
• Piramal Pharma Solutions: Piramal Pharma Solutions operates a global CDMO platform offering API development and manufacturing services across the value chain, comparable to Uquifa in CDMO scope and customer segments.
• Cambrex: Cambrex is a US-headquartered CDMO specializing in small-molecule API development and manufacturing from clinical to commercial scale, with a similar customer profile to Uquifa's CDMO business.
• Dishman Carbogen Amcis: Dishman Carbogen Amcis is an India-headquartered CDMO/API manufacturer offering process development, scale-up, and commercial API manufacturing with European manufacturing presence - highly comparable in CDMO scope and customer base.
• Olon Group: Olon is an Italy-based private API manufacturer with a large generic API portfolio and multi-site GMP manufacturing in Europe, India, and the US - a highly comparable European-headquartered competitor in generic APIs and CDMO.
• Siegfried Holding: Siegfried is a Swiss-listed API manufacturer offering both generic APIs and full-service CDMO, with global manufacturing footprint and DMF portfolios - the closest public-market comparable to Uquifa's dual API/CDMO model.

Broad incumbents

• Lonza Group: Lonza is the world's largest CDMO offering API and biologics development and manufacturing services - a global incumbent whose small-molecule API services compete with Uquifa's CDMO franchise.
• Johnson Matthey (Pharma & CDMO): Johnson Matthey's Health sector includes a CDMO/API business offering small-molecule API development and manufacturing - a broader incumbent with significant scale and resources relative to Uquifa.

Emerging players

• PolyPeptide Group: PolyPeptide Group is a Switzerland-based manufacturer of peptides and small molecules for pharma, offering GMP API manufacturing services that overlap partially with Uquifa's API portfolio.
• Industria Chimica Emiliana (ICE Group): ICE Group is an Italy-based manufacturer specializing in generic and custom APIs with a similar mid-sized European footprint to Uquifa, comparable in regulatory filings and product scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/uquifa

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Uquifa